Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Recruiting · Phase 2 · NCT06699849
Conditions: Sickle Cell Disease Vaso-occlusive Crisis
At a glance
- Research payments reported, 2025
- $400,882
- U.S. investigators named
- 18
- Sites paid
- 16
- Planned or actual enrollment
- 70
About the trial
- Sponsor
- CSL Behring
- Tested
- CSL889 (biological), Placebo (drug)
- Dates
- Started 2025-07-10; completion 2027-10-22
- Results posted
- Not yet
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.
From ClinicalTrials.gov, last updated 2026-10-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $400,882 in research payments for this study in 2025 (167 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Carolyn S. Saccente, MD Pediatric Hematology & Oncology · Little Rock, AR
- Zahra Pakbaz, MD Hematology · Orange, CA
- Robin E. Miller, MD Pediatric Hematology & Oncology · Wilmington, DE
- Gershwin T. Blyden, M.D. Internal Medicine · Miami, FL
- Thomas J. Harrington, MD Hematology & Oncology · Miami, FL
- Richard G. Wilkerson, M.D. Emergency Medicine · Baltimore, MD
- Joseph B. Miller, MD Emergency Medicine · Detroit, MI
- James H. Paxton, M.D. Emergency Medicine · Detroit, MI
- Ramasubramanian V. Kalpatthi, MD Pediatric Hematology & Oncology · Kansas City, MO
- Caroline E. Freiermuth, MD Emergency Medicine · Durham, NC
- John J. Strouse, M.D. Pediatric Hematology & Oncology · Durham, NC
- Ellen W. Friedman, MD Hematology · Bronx, NY
- Kenneth Rivlin Pediatric Hematology & Oncology · New York, NY
- Jonathan Schimmel, MD Emergency Medicine · New York, NY
- Jennifer E. Vaughn, MD Hematology · Columbus, OH
- Laura M. Decastro, M.D. Hematology · Pittsburgh, PA
- Thokozeni Lipato, MD Internal Medicine · Richmond, VA
- David C. Brousseau, MD Pediatric Emergency Medicine · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UPMC Hillman Cancer Center $70,465
- Biomedical Research Alliance of New York $48,050
- The Ohio State University C/o Wexner Medical Center $41,948
- Uci Health-Orange, CA $40,302
- University of Cincinnati $37,810
- Arkansas Children's Research Institute $32,325
- University of Maryland Baltimore $30,779
- Virginia Commonwealth University Health System Medical Center $28,423
- University of Miami Dba Umsponsored Programs $25,070
- Lincoln Medical & Mental Health Center, NY $14,300
- Detroit Trauma Symposium - Wsu Surgery Department $12,949
- Duke University $5,210
- Nemours Children's Hospital, Delaware $5,210
- Henry Ford Health Hospital, MI $4,552
- The Foundation for Sickle Cell Disease $3,371
- Mount Sinai Medical Center $118
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.